Ipsen : and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders -Today at 11:14 am

Ipsen obtains exclusive options to Spherical Nucleic Acids currently under discovery evaluation for Huntington's disease and Angelman syndrome




Exicure...

Related Keywords

United States ,Chicago ,Illinois ,Cambridge ,Cambridgeshire ,United Kingdom ,France ,Crawford ,South Lanarkshire ,Philippe Lopes Fernandes ,Ipsen Euronext ,David Giljohann ,Exicure Inc ,Nasdaq ,Spherical Nucleic Acids ,Chief Business Officer ,Chief Executive Officer ,Reviews Drug Discovery ,Markets ,